These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38302341)
21. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it? Xu R; Wang W; Zhang W Front Public Health; 2022; 10():1039123. PubMed ID: 36504951 [TBL] [Abstract][Full Text] [Related]
22. Comparative Analysis of Conformational Dynamics and Systematic Characterization of Cryptic Pockets in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB.1 Spike Complexes with the ACE2 Host Receptor: Confluence of Binding and Structural Plasticity in Mediating Networks of Conserved Allosteric Sites. Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G Viruses; 2023 Oct; 15(10):. PubMed ID: 37896850 [TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals. Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141 [TBL] [Abstract][Full Text] [Related]
24. Omicron variant evolution on vaccines and monoclonal antibodies. Sabbatucci M; Vitiello A; Clemente S; Zovi A; Boccellino M; Ferrara F; Cimmino C; Langella R; Ponzo A; Stefanelli P; Rezza G Inflammopharmacology; 2023 Aug; 31(4):1779-1788. PubMed ID: 37204696 [TBL] [Abstract][Full Text] [Related]
25. An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China. Zhang M; Chen Z; Zhou J; Zhao X; Chen Y; Sun Y; Liu Z; Gu W; Luo C; Fu X; Zhao X Biosaf Health; 2022 Dec; 4(6):406-409. PubMed ID: 36320663 [TBL] [Abstract][Full Text] [Related]
26. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections. Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T Viruses; 2023 May; 15(6):. PubMed ID: 37376600 [TBL] [Abstract][Full Text] [Related]
27. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885 [TBL] [Abstract][Full Text] [Related]
28. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice. Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552 [TBL] [Abstract][Full Text] [Related]
29. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380 [TBL] [Abstract][Full Text] [Related]
33. Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January-March 2022. Loconsole D; Centrone F; Sallustio A; Accogli M; Casulli D; Sacco D; Zagaria R; Morcavallo C; Chironna M Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632430 [TBL] [Abstract][Full Text] [Related]
34. Quantitative Mutation Analysis of Genes and Proteins of Major SARS-CoV-2 Variants of Concern and Interest. Liang F Viruses; 2023 May; 15(5):. PubMed ID: 37243278 [TBL] [Abstract][Full Text] [Related]
35. Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice. Wang Y; Wang B; Zhao Z; Xu J; Zhang Z; Zhang J; Chen Y; Song X; Zheng W; Hou L; Wu S; Chen W Viruses; 2023 Mar; 15(3):. PubMed ID: 36992472 [TBL] [Abstract][Full Text] [Related]
36. Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding. Popovic M BioTech (Basel); 2022 Oct; 11(4):. PubMed ID: 36278557 [TBL] [Abstract][Full Text] [Related]
37. The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron. Wiegand T; Nemudryi A; Nemudraia A; McVey A; Little A; Taylor DN; Walk ST; Wiedenheft B Viruses; 2022 Sep; 14(9):. PubMed ID: 36146815 [TBL] [Abstract][Full Text] [Related]
38. Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants. Roy U Pathogens; 2023 Dec; 13(1):. PubMed ID: 38276156 [TBL] [Abstract][Full Text] [Related]